Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-tagatose is a naturally occurring monosaccharide and a rare sugar that is an epimer of D-fructose. It is approximately 90% as sweet as sucrose but provides only about one-third the calories. D-tagatose is approved as a low-calorie sweetener and food additive in several countries. Its mechanism of action involves poor absorption in the small intestine (only 15–20% absorbed), with most of the ingested amount fermented by colonic microflora to short-chain fatty acids[2][1]. In clinical studies, d-tagatose has been shown to reduce postprandial glycemia and HbA1c levels in patients with type 2 diabetes by attenuating intestinal glucose absorption and possibly interfering with carbohydrate transport[1][3]. It may also improve lipid profiles by reducing total cholesterol, VLDL, LDL cholesterol, and increasing HDL cholesterol[1][3]. Additional properties include prebiotic effects on gut flora and potential antioxidant activity[3]. The compound has been investigated for obesity control due to its ability to increase satiety via reduced carbohydrate absorption[3]. Spherix has investigated it for pharmaceutical use in obesity and type II diabetes; it reached phase 3 clinical trials for type 2 diabetes treatment[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-tagatose.